Publications
2008
Finally: The digital, democratic age of scientific abstracts.
Superti-Furga G,
Wieland F,
Cesareni G.
FEBS Lett., 2008 Apr 9;582(8):1169.
2008
The DEAD-box helicase DDX3 is a TBK1 substrate required for IFN-beta production.
Soulat D,
Bürckstümmer T,
Westermayer S,
Goncalves A,
Bauch A,
Stefanovic A,
Hantschel O,
Bennett KL,
Decker T,
Superti-Furga G.
EMBO J, 2008 Aug 6;27(15):2135–46.
2008
Characterization of BCR-ABL deletion mutants from patients with chronic myeloid leukemia.
Sherbenou DW,
Hantschel O,
Turaga L,
Kaupe I,
Willis S,
Bumm T,
Press RD,
Superti-Furga G,
Druker BJ,
Deininger MW.
Leukemia, 2008 Jun;22(6):1184–90.
2008
The effects of dasatinib on IgE receptor-dependent activation and histamine release in human basophils.
Kneidinger M,
Schmidt U,
Rix U,
Gleixner KV,
Vales A,
Baumgartner C,
Lupinek C,
Weghofer M,
Bennett KL,
Herrmann H,
Schebesta A,
Thomas WR,
Vrtala S,
Valenta R,
Lee FY,
Ellmeier W,
Superti-Furga G,
Valent P.
Blood, 2008 Jan 7; PMID: 18180381.
2008
Target spectrum of the BCR-ABL inhibitors imatinib, nilotinib and dasatinib.
Hantschel O,
Rix U,
Superti-Furga G.
Leuk Lymphoma, 2008 Apr;49(4):615-9. Review.
2008
The chemokine IL-8 and the surface activation protein CD69 are markers for Bcr-Abl activity in CML.
Hantschel O,
Gstoettenbauer A,
Colinge J,
Kaupe I,
Bilban M,
Burkard TR,
Valent P,
Superti-Furga G.
Molecular Oncology, Vol 2/Issue3/ October 2008, 272–281.
2008
Structural coupling of Fes and Abl SH2-tyrosine kinase domains links substrate recognition and kinase activation.
Filippakopoulos P,
Kofler M,
Hantschel O,
Gish GD,
Grebien F,
Salah E,
Neudecker P,
Kay LE,
Turk BE,
Superti-Furga G,
Pawson T,
Knapp S.
Cell. 2008 Sep 5;134(5): 793–803.
2008
Intrinsic differences between the catalytic properties of the oncogenic NUP214-ABL1 and BCRABL1 fusion protein kinases.
De Keersmaecker K,
Versele M,
Cools J,
Superti-Furga G,
Hantschel O.
Leukemia. 2008, Dec;22(12):2208–16.
